Review Article

Detection and Control of Prion Diseases in Food Animals

Table 2

Comparative analysis of in vitro and ex vivo immunotherapeutic investigations of prion diseases.

RegionModelEfficacyReference

mAb 3F4 (109–113)
pSera; 23–33, 90–104, 143–156, 219–232
Cell-free conversionpSera 219–232 disrupted formation of new PrPScGilch et al. 2003 [178]
mAb 6H4 (144–152)ScN2a cell lineClearance of PrPSc from cell line following antibody treatmentEnari et al. 2001 [177]
Fab D18 (132–156)ScN2a cell lineBlocked PrPSc formation and cleared existing PrPScPeretz et al. 2001 [179]
In vitroSAF34 (octarepeat) SAF61 (144–152)ScN2a cell line overexpressing PrPCBoth Abs decreased PrPSc and PrPC in infected and uninfected cellsPerrier et al. 2004 [180]
Panel of antibodies to PrPC and PrPSc generated in PrP0/0 miceScN2a cell lineCapacity for protection independent of epitope but dependent on ability to bind cell surface PrPC to prevent internalizationKim et al. 2004 [181]
ER targeted scFv of 8H4 (175–185) and 8F9 (225–231)Expression in PC12 cell lineInhibition of PrPC translocation to cell surface; prevented PrPSc accumulationCardinale et al. 2005 [182]
mAbs to “YYR” motifScN2a cell lineReduced content of PrPScCashman and Caughey 2004 [168]

Ex vivoPrPC poly Ab ex vivo neutralizationGolden hamster2-log reductionGabizon et al. 1988 [174]
Fab D18 (132–156)
Ex vivo neutralization
ScN2a cell lineMice lived 3 months longer (3-log reduction of infectivity)Peretz et al. 2001 [179]